Emerging Non-injectable Insulin Market Trends: Innovative Advancements In Non-Injectable Insulin Delivery Shaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Non-injectable Insulin Market Size Growth Forecast: What to Expect by 2025?
The market for non-injectable insulin has seen significant expansion in the past few years. From being valued at $1.92 billion in 2024, it is projected to rise to $2.14 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.1%. The historical growth of this market can be traced back to factors such as better patient compliance, management of needle fear, improved quality of life, simpler administration techniques, and consistent control of blood sugar levels.

How Will the Non-injectable Insulin Market Size Evolve and Grow by 2029?
Expectations are high for robust expansion in the non-injectible insulin market in the upcoming years. The market is projected to escalate to "$3.11 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The surge during the projected timeline is linked to sustained focus on patient compliance, ongoing resolutions for needle fears, further enhancements in quality of life, ongoing advancements in safety measures, and lower risks of infections and injuries. Over the forecast period, leading trends encompass technological progress, the evolution of tech solutions, integration of digital health, applications of nanotechnology, and combined therapy methods.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

What Drivers Are Propelling the Growth of Non-injectable Insulin Market Forward?
The growth of the non-injectable insulin market is predicted to be fuelled by the escalating issues of obesity and diabetes. Obesity refers to a health condition where there is an excessive build-up of body fat resulting from an energy intake and expenditure imbalance, and diabetes, often simply known as diabetes mellitus, is a cluster of metabolic disorders causing high sugar levels in the blood for extended periods. Non-injectable insulin is employed for treating both obesity and diabetes, offering the possibility of enhanced management by tackling insulin therapy obstacles, providing potential weight control benefits, and more accessible treatment methods. For example, the World Heart Federation, situated in Switzerland, reported in 2022 that the global obesity rate is predicted to swell, with an estimated count of 2.3 billion people, children and adults included, grappling with overweight and obesity issues in 2021, a number anticipated to climb to 2.7 billion by 2025. Moreover, a report released in April 2023 by the British Diabetic Association, a diabetes charity based in the UK, states that there are 4.3 million diabetes patients in the UK, and an additional 2.4 million UK residents are seriously at risk of getting type 2 diabetes. The recorded numbers for 2021-22 show an increase of 148,951 compared to the preceding year. As such, the escalating problems of obesity and diabetes contribute to the expansion of the non-injectable insulin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What Trends Will Shape the Non-injectable Insulin Market Through 2029 and Beyond?
The leading businesses in the non-injectable insulin market are concentrating their efforts on the development of innovative drug delivery systems, including a needle-free oral insulin spray, to enhance the quality of life for individuals who control their diabetes with several insulin injections. A needle-less oral insulin spray is a pain-free approach to blood glucose regulation and provides a simple alternative, as the doses can be administered directly into the mouth. For example, in November 2023, NiedlFree Technologies, a technology firm based in India, launched Ozulin, an oral insulin spray product. This product is designed to provide a more accessible solution for those with diabetes, especially those who may struggle with the standard insulin injection methods. If approved, Ozulin could revolutionize the lives of diabetics by providing a simpler and painless alternative to insulin injections.

What Are the Key Segments in the Non-injectable Insulin Market?
The non-injectable insulin market covered in this report is segmented -

1) By Type: Synthetic Insulin, Semi Synthetic Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:
1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin
2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

Who Are the Key Players Shaping the Non-injectable Insulin Market's Competitive Landscape?
Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

What Geographic Markets Are Powering Growth in the Non-injectable Insulin Market?
North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.